Cephalon Approaches CIMA Labs To Resuscitate Merger Talks
This article was originally published in The Tan Sheet
Executive Summary
Cephalon is attempting to restart talks with CIMA Laboratories regarding a potential acquisition of the company with a Sept. 10 letter sent to CIMA's board
You may also be interested in...
CIMA Labs reconsiders
CIMA Labs says "there is a reasonable likelihood" that an unsolicited acquisition offer from Rx drug maker Cephalon "would reasonably be expected to result in a superior proposal" to an already-agreed upon stock-swap transaction with aaiPharma, according to a Sept. 19 release. Cephalon sent a letter to CIMA's board on Sept. 10 asking them to reconsider their decision to reject the Rx firm's proposal (1"The Tan Sheet" Sept. 15, 2003, p. 7). aaiPharma remains "committed" to completing the merger with CIMA, the company said in a statement...
CIMA Shareholder Suits Follow Firm’s Rejection Of Cephalon Merger Offer
Two class action shareholder lawsuits filed after CIMA Labs rejected Cephalon's acquisition offer could complicate the firm's proposed merger with aaiPharma
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC